SenesTech, Inc.(SNES)Earnings, Financials & Key Ratios

Key Thesis Takeaways

• SenesTech demonstrates a proprietary competitive advantage through its rodent control technology, yet the firm struggles to achieve operational leverage as SG&A expenses consistently dwarf gross profits.
• The company's reliance on external equity financing to offset a $144.5 million accumulated deficit suggests a precarious long-term financial trajectory.
• Investors should monitor whether the firm can stabilize its volatile revenue growth, which fluctuated from a 16.0% contraction in 2025Q4 to a 78.1% expansion in 2024Q1, before committing capital to this high-risk specialty chemical play.